- Home
- OFIX vs EDIT Comparison
OFIX vs EDIT Comparison
Compare OFIX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OFIX | EDIT |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 432.8M |
| IPO Year | 1998 | 2016 |
Fundamental Metrics
Financial Performance| Metric | OFIX | EDIT |
|---|---|---|
| Price | $9.73 | $2.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $17.25 | $5.30 |
| AVG Volume (30 Days) | 484.3K | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.39 | ★ 37.50 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $822,312,000.00 | $31,937,000.00 |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $6.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.85 | ★ 132.64 |
| 52 Week Low | $9.13 | $1.66 |
| 52 Week High | $16.99 | $4.54 |
Technical Indicators
Market Signals| Indicator | OFIX | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 39.42 |
| Support Level | $9.13 | $1.93 |
| Resistance Level | $12.72 | $2.63 |
| Average True Range (ATR) | 0.63 | 0.35 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 28.54 | 3.59 |
Price Performance
Historical ComparisonAbout OFIX Orthofix Medical Inc. (DE)
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.